Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Mild to Moderate Plaque Psoriasis

Next Previous
Trial Profile

A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Mild to Moderate Plaque Psoriasis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Sep 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apremilast (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Acronyms ADVANCE
  • Sponsors Amgen; Celgene Corporation

Most Recent Events

  • 30 Aug 2022 According to an Amgen media release, data from this trial will be presented at the 31st European Academy of Dermatology and Venereology (EADV) 2022.
  • 25 Mar 2022 According to an Amgen media release, data will be presented at the American Academy of Dermatology (AAD) congress.
  • 20 Dec 2021 According to an Amgen media release, based on the results of this study, the USA Food and Drug Administration (FDA) has approved Otezla (apremilast) for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top